Review Article
Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians
Table 2
Pharmacologic profiles of new oral anticoagulants in clinical use.
| | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
| Target | Thrombin | Factor Xa | Xa | Xa | Administration | Once or twice daily | Once daily | Twice daily | Once daily | Prodrug | Yes | No | No | No | Half-life (hours) | 12–17 | 5–9 | 8–15 | 9–11 | (hours) | 0.5–2 | 2–4 | 3-4 | 1-2 | Bioavailability | 3–7% | 66–100% | 50% | 50% | Protein binding | 35% | 92–95% | 87% | 40–59% | Renal excretion | 80% | 33% | 27% | 35% |
|
|
: time to peak.
|